WO2004043435A3 - Systemic delivery of antiviral agents - Google Patents

Systemic delivery of antiviral agents Download PDF

Info

Publication number
WO2004043435A3
WO2004043435A3 PCT/US2003/036637 US0336637W WO2004043435A3 WO 2004043435 A3 WO2004043435 A3 WO 2004043435A3 US 0336637 W US0336637 W US 0336637W WO 2004043435 A3 WO2004043435 A3 WO 2004043435A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
risk
treating
reducing
antiviral agents
Prior art date
Application number
PCT/US2003/036637
Other languages
French (fr)
Other versions
WO2004043435A2 (en
Inventor
Paul Ashton
Jianbing Chen
Thomas J Smith
Original Assignee
Control Delivery Sys Inc
Paul Ashton
Jianbing Chen
Thomas J Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Sys Inc, Paul Ashton, Jianbing Chen, Thomas J Smith filed Critical Control Delivery Sys Inc
Priority to AU2003287666A priority Critical patent/AU2003287666A1/en
Publication of WO2004043435A2 publication Critical patent/WO2004043435A2/en
Publication of WO2004043435A3 publication Critical patent/WO2004043435A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The systems and methods disclosed herein provide sustained delivery of a therapeutic agent for treating a patient, e.g., human, to obtain a desired local or systemic physiological or pharmacological effect. Method includes positioning the sustained released drug delivery system at an area wherein release of the agent is desired and allowing the agent to pass through the device to the desired area of treatment. In some embodiments, the method is for treating or reducing the risk of retroviral or lentiviral infection. In certain embodiments, the method is for preventing or reducing the risk of mother-to-child transmission of HIV, wherein the therapeutic agent is an antiviral agent.
PCT/US2003/036637 2002-11-13 2003-11-13 Systemic delivery of antiviral agents WO2004043435A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003287666A AU2003287666A1 (en) 2002-11-13 2003-11-13 Systemic delivery of antiviral agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42594302P 2002-11-13 2002-11-13
US60/425,943 2002-11-13

Publications (2)

Publication Number Publication Date
WO2004043435A2 WO2004043435A2 (en) 2004-05-27
WO2004043435A3 true WO2004043435A3 (en) 2004-07-08

Family

ID=32313080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036637 WO2004043435A2 (en) 2002-11-13 2003-11-13 Systemic delivery of antiviral agents

Country Status (2)

Country Link
AU (1) AU2003287666A1 (en)
WO (1) WO2004043435A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
UA97971C2 (en) 2007-06-08 2012-04-10 Берингер Ингельхайм Интернациональ Гмбх Extended release formulation of nevirapine
WO2010135369A1 (en) * 2009-05-18 2010-11-25 Dose Medical Corporation Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN102740830A (en) * 2009-12-23 2012-10-17 普西维达公司 Sustained release delivery devices
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EA201490837A1 (en) 2011-10-21 2014-11-28 Эббви Инк. METHODS OF TREATING HCV, INCLUDING, AT THE LITERATURE, TWO ANTI-VIRAL AGENTS OF DIRECT ACTION, RIBAVIRIN, BUT NOT INTERFERON
DE112012003457T5 (en) 2011-10-21 2015-03-12 Abbvie Inc. Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV)
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
EP3148494A4 (en) * 2014-05-30 2017-12-20 Textile-Based Delivery, Inc. Drug delivery systems and related methods of use
BR112017007942A2 (en) 2014-10-30 2017-12-19 Textile Based Delivery Inc release systems
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017184881A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices

Also Published As

Publication number Publication date
WO2004043435A2 (en) 2004-05-27
AU2003287666A1 (en) 2004-06-03
AU2003287666A8 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
WO2004043435A3 (en) Systemic delivery of antiviral agents
WO2004091444A3 (en) Implantable medical device comprising therapeutic agents with different diffusion rates
WO2003082188A3 (en) Methods and drug delivery systems for the treatment of orofacial diseases
EP1982701A3 (en) Sustained Release Drug Delivery Devices, Methods of Use, and Methods of Manufacturing Thereof
NO20034684D0 (en) Device for administering funds through the stratum corcum
WO2004010975A3 (en) Controlled drug delivery
WO2003077972A8 (en) Implantable drug delivery system
NO962833D0 (en) Transdermal preparation comprising polyvinylpyrrolidine
WO2006036982A3 (en) Drug delivery coating for use with a stent
DE60136910D1 (en) DEVICE WITH ENERGY CONVERSION DEVICES FOR IMPOTENA TREATMENT
WO2005079387A3 (en) Implantable drug delivery device including wire filaments
WO2003028660A3 (en) Drug delivery devices and methods
HUP9802773A2 (en) Transcorneal drug-release system
WO2000038714A8 (en) The prevention and treatment of retinal ischemia and edema
CA2424029A1 (en) Coated medical devices
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
MXPA05008461A (en) Kit for applying drug coating to a medical device in surgeon room.
WO2006009776A3 (en) Reusable support device with therapeutic inserts
WO2007030478A3 (en) Implantable device for therapeutic treatment within a body lumen
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
AU3401093A (en) Therapeutic agent for threatened abortion
CY1106702T1 (en) USE OF A COMBINATION OF A PURINE AND A NITROGEN MONOXIDE DONATOR FOR THE PREVENTION OR TREATMENT OF BENEFITS OF BENEFITS
WO2002007760A3 (en) Therapeutic agent against aids comprising anti hiv goat antibody
James New double vs. triple antiviral combination study, CD4 200-500, no prior treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP